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ABSTRACT
Objective: To verify whether vaccination against the
A-H1N1 virus in the paediatric population was effective
in preventing the occurrence of inﬂuenza-like illness
(ILI) or was associated with adverse events of special
interest.
Design, setting and patients: A caseecontrol
analysis was performed as part of surveillance of
children hospitalised through the emergency
departments of eight paediatric hospitals/wards for ILI,
neurological disorders, non-infectious muco-
cutaneous diseases and vasculitis, thrombocytopaenia
and gastroduodenal lesions.
Results: Among 736 children enrolled from November
2009 to August 2010, only 25 had been vaccinated
with the pandemic vaccine. Out of 268 children
admitted for a diagnosis compatible with the adverse
events of special interest, six had received the A-H1N1
vaccine, although none of the adverse events occurred
within the predeﬁned risk windows. Only 35 children
out of 244 admitted with a diagnosis of ILI underwent
laboratory testing: 11 were positive and 24 negative for
the A-H1N1 virus. None of the A-H1N1 positive
children had received the pandemic vaccine. The OR of
ILI associated with any inﬂuenza vaccination was 0.9
(95% CI 0.1 to 5.5).
Conclusions: The study provides additional
information on the beneﬁterisk proﬁle of the pandemic
vaccine. No sign of risk associated with the inﬂuenza
A-H1N1 vaccine used in Italy was found, although
several limitations were observed: in Italy, pandemic
vaccination coverage was low, the epidemic was
almost over by mid December 2009 and the A-H1N1
laboratory test was performed only during the
epidemic phase (in <10% of children). This study
supports the importance of the existing network of
hospitals for the evaluation of signals relevant to new
vaccines and drugs.
BACKGROUND
Great concern about the severity of the
A-H1N1 inﬂuenza epidemic in the paediatric
population was expressed at international level
in 2009.
1 2 The main public health response
was considered to be the development of
and access to new vaccines against the
A-H1N1 virus. However, due to the limited
availability of data, there was widespread
uncertainty about the efﬁcacy and safety of
the pandemic vaccines, which could not be
resolved in the short time available before
vaccine approval, even though authorities
had laid down the procedures to be
completed in case of a new epidemic.
3
To ensure public safety during the inﬂu-
enza outbreak, rapid access to the new
inﬂuenza A-H1N1 vaccines was offered to
high-risk groups such as pregnant women,
young infants and immune-compromised
patients. There were also speciﬁc concerns
about the potential risks of adverse events
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ARTICLE SUMMARY
Article focus
- To assess the effectiveness of the inﬂuenza
A-H1N1 vaccine and the occurrence of adverse
events of special interest in the paediatric
population.
Key messages
- During the 2009e2010 inﬂuenza season, very
limited information was available on the safety
and effectiveness of the inﬂuenza A-H1N1
vaccine.
- Together with other post-marketing studies, our
ﬁndings provide additional information on the
beneﬁterisk proﬁle of the pandemic vaccine.
Strengths and limitations of this study
- The study focused on inﬂuenza-like illness and
adverse events of special interest that were
sufﬁciently severe to cause hospitalisation in
children and provided additional information on
the beneﬁterisk proﬁle of the pandemic vaccine.
- A-H1N1 vaccination coverage in Italy during the
2009e2010 inﬂuenza season was very low, with
around 4% of the general population and only
3.7% of the children included in this study having
been vaccinated.
- The inﬂuenza outbreak was almost over by the
ﬁrst half of December 2009, and both the
incidence and severity of the disease were
lower than expected.
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Open Access Researchassociated with the adjuvant included in some of the A-
H1N1 vaccines and with the concomitant use of other
inﬂuenza vaccines.
Regulatory agencies around the world require
companies to carry out post-marketing surveillance
studies on newly developed vaccines. However, because
of the limited time available during this emergency,
research groups already involved in the efﬁcacy and
safety assessment of drugs and vaccines were invited to
focus their activities on the pandemic vaccines.
4 In Italy,
a national pharmacovigilance pandemic plan, with
speciﬁc focus on safety in the paediatric population, was
implemented.
5
Active surveillance of the role of drugs and vaccines
in the occurrence of selected clinical conditions
responsible for paediatric hospitalisation has been
conducted in Italy since 1999. This surveillance so far
has proved useful in the detection, description and
evaluation of risk signals associated with drugs and
vaccines used in children.
6e8 During the 2009e2010
pandemic season, following the launch of the vaccina-
tion campaign by the Italian Ministry of Health,
5 the
study protocol of the existing surveillance system was
adapted to focus on and include evaluation of the safety
and efﬁcacy of the A-H1N1 vaccine. In Italy the immu-
nisation campaign started in October in healthcare
workers and was subsequently extended to pregnant
women and other at-risk groups, including children.
After some weeks vaccination was offered to all citizens.
Focetria, administered free of charge by the Italian
NHS, was the only available pandemic vaccine.
The purpose of this study was to assess effectiveness of
inﬂuenza A-H1N1 vaccination in the paediatric popula-
tion for preventing the occurrence of inﬂuenza-like
illnesses (ILI) requiring hospitalisation. Moreover,
we assessed the safety of the vaccine, in particular by
evaluating all the adverse events of special interest
(AESI) reported in the exposed population.
METHODS
Study population
This study consisted of active surveillance of children
hospitalised from November 2009 to August 2010
through the emergency departments (EDs) of eight
clinical centres for selected conditions, regardless of
their previous drug and vaccine exposure. The study
population consisted of all children (aged 1 monthe18
years) admitted for the four following conditions: (i)
neurological disorders; (ii) non-infectious muco-cuta-
neous diseases and vasculitis; (iii) thrombocytopaenia;
and (iv) conﬁrmed gastroduodenal lesions (and/or
clinically deﬁned haematemesis or melena). The ﬁrst
three conditions cover nearly all diagnoses compatible
with vaccine related AESI and were considered for
vaccine safety evaluation.
Children older than 6 months hospitalised for ILI, as
judged by the clinicians in the ED, were also enrolled in
the study to estimate the effectiveness of inﬂuenza
A-H1N1 vaccination. For children >5 years of age, the
following deﬁnition of ILI was adopted: sudden onset of
fever $388C (for at least 24 h) in association with at least
one respiratory symptom (cough, sore throat, coryza)
and at least one general symptom (headache, asthenia,
malaise). For children between 6 months and 5 years of
age, in association with fever >388C, the following
general sign and symptoms were considered: inadequate
drinking or feeding, vomiting and/or diarrhoea and
respiratory symptoms.
9
Assessment of the presence of inﬂuenza A-H1N1 virus
by laboratory test was not an inclusion requirement.
Both clinically deﬁned and laboratory conﬁrmed hospi-
talisations for ILI were considered of interest in evalu-
ating the effectiveness of the inﬂuenza vaccines.
10 Given
the non-interventional nature of the study design, we
had to rely on the usual practice of participating hospi-
tals. Moreover, following a recommendation of the
Italian Ministry of Health, laboratory conﬁrmation of
A-H1N1 virus was not routinely suggested after the
epidemic began to decline (mid December 2009)
(ﬁgure 1). In order to limit selection bias (ie, selective
enrolment of vaccinated children), participating centres
were asked to enrol ILI cases on a speciﬁed day of the
week (up to three or four consecutive cases per week)
blind to vaccination status. This recruitment strategy
applied to all ILI cases and was independent of the
decision to carry out laboratory conﬁrmation.
Data source
After providing informed consent, parents were inter-
viewed by a trained investigator, using a structured
questionnaire, during the hospital admission of the
child. The interview sought to obtain the relevant history
and to ascertain drug use and vaccination status. As
reported in the study protocol, the information on drug
and vaccine exposure was not validated.
For drug exposure, the time window of interest was the
3 weeks before the onset of symptoms related to the
hospital admission. With regard to vaccine exposure, the
12 weeks preceding the hospitalisation were considered
of interest for all non-inﬂuenza vaccines. For the assess-
ment of the effectiveness of both the A-H1N1 and
seasonal inﬂuenza vaccines, children were considered
exposed if vaccinated any time before admission. To
evaluate any possible relationship between vaccination
and AESIs, time windows speciﬁc for each AESI were
considered, for example 0e2 days for urticaria¸
0e14 days for convulsions and 0e42 days for thrombo-
cytopaenia, vasculitis, neuropathies, etc.
11 12
Data analysis
Two different comparisons were conducted to assess
vaccine effectiveness and estimate the ORs. For the ﬁrst
comparison, all children hospitalised for ILI were
considered as cases, while children >5 months old
enrolled for any of the four clinical conditions described
above acted as controls. For the second comparison, the
analysis was restricted to all children admitted for ILI
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a positive test were considered as cases, while those with
a negative test acted as controls. The purpose of the ﬁrst
analysis was to provide an estimate of the effectiveness of
the vaccines in preventing hospitalisation for any ILI
during the inﬂuenza season. The second analysis was
aimed at estimating the ability of the A-H1N1 vaccine to
prevent the occurrence of conﬁrmed episodes of
pandemic inﬂuenza.
Assuming 50% of children were vaccinated, a power of
90% and an a error of 0.05, a sample size of 194 hospi-
talisations for ILI was required to estimate a reduction of
at least 50% in the occurrence of ILI among vaccinated
children (OR#0.5).
Adjusted ORs and related 95% CIs were calculated
through a multivariate logistic model. Data were
analysed with SPSS V.17.
Study sites
The following paediatric hospitals and departments
participated in the study: Giannina Gaslini Paediatric
Hospital (Genoa), Regina Margherita Paediatric
Hospital (Turin), Department of Paediatrics, University
of Padua (Padua), Anna Meyer Children’s University
Hospital (Florence), Pharmacology and Paediatrics and
Developmental Neuroscience, Universita ` Cattolica Sacro
Cuore (Rome), Emergency Department, Bambino Gesu `
Children Hospital (Rome), Santobono-Pausilipon
Paediatric Hospital (Naples) and Giovanni Di Cristina
Paediatric Hospital (Palermo). The protocol of the study
was submitted to the ethics committee of each clinical
centre for approval. The eight centres account for
around 350000 ED visits annually (around 50000 chil-
dren are subsequently hospitalised through the ED) and
are located in northern, central and southern Italy. The
study was coordinated by the National Centre of Epide-
miology of the National Institute of Health.
RESULTS
From 1 November 2009 to 31 August 2010, 736 children,
with a median age of 4 years (range 1 monthe18 years),
were enrolled. Overall, 492 children were hospitalised
for at least one of the four conditions of interest in this
study: 241 (49%) for neurological disorders, 144 (29%)
for muco-cutaneous diseases, 60 (12%) for thrombocy-
topaenia and 47 (10%) for gastro-duodenal lesions. A
total of 244 children were admitted with a diagnosis of
ILI (table 1). The male to female ratio was largely similar
in the different diagnostic groups.
Among those with neurological conditions, convulsion
was the most frequent cause of admission (N¼91; 38%),
followed by disturbances of vigilance and consciousness,
for example, numbness, somnolence and lipothymia
(N¼39; 16%) and by apparent life threatening events
(N¼30; 12%). Some children with serious clinical
conditions were admitted: eight with peripheral
neuropathies and ﬁve with Guillain-Barre ´ syndrome.
More than half of those with muco-cutaneous diseases
had Schoenlein-Henoch purpura or other vasculitis
(N¼80; 55%), followed by urticaria (N¼32; 22%) and
erythema (N¼15; 10%).
Of the children enrolled in the study, 71% had been
exposed to at least one drug in the 3 weeks preceding
hospital admission. A total of 173 children (24%) had
been vaccinated before hospitalisation (either at any time
for the inﬂuenza vaccines or during the preceding
12 weeks for the other vaccines). Hexavalent vaccine was
most frequently reported (55 children), followed by the
antipneumococcal (37 children) and MMR (24 children)
vaccines.
For the inﬂuenza vaccine analysis, the denominator
was limited to the 683 children at least 6 months of age
(according to the vaccination schedule for the pandemic
vaccine). In this population (244 admitted for ILI and
439 for the other conditions), 25 children (3.7%) had
Figure 1 Effectiveness and
safety of the A-H1N1 vaccine.
y, years. Adapted from http://www.
iss.it/binary/iﬂu/cont/2009_2010.pdf.
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two doses) and 45 (6.6%) had been vaccinated against
seasonal inﬂuenza. Eleven children received both
vaccines and in nine children the type of inﬂuenza
vaccine was not speciﬁed. All immunised children (those
with ILI and controls) had received the inﬂuenza
vaccines more than 14 days before hospitalisation.
Out of 268 children admitted for a diagnosis compat-
ible with AESI, only six had been previously vaccinated
with the A-H1N1 vaccine (two cases of urticaria, two
convulsions, one vasculitis and one Schoenlein-Henoch
purpura), however, all admissions occurred outside the
predeﬁned risk windows (table 2).
Regarding evaluation of the effectiveness of the
pandemic vaccine to prevent ILI episodes, regardless of
any positive laboratory test, all estimates were above 1
(table 3). Speciﬁcally, the adjusted ORs were 2.1 (95% CI
1.1 to 4.1) for the seasonal vaccine and 1.3 (95% CI 0.6
to 3.1) for the pandemic vaccine. No difference in the
OR estimates was observed when the analysis was
restricted to the pandemic period (ie, October
2009eJanuary 2010).
Among the 35 children who underwent laboratory
testing, 11 were positive and 24 negative for the A-H1N1
virus (table 4). Since none of the A-H1N1 positive chil-
dren had a positive history for A-H1N1 vaccination, it was
not possible to obtain an estimate of vaccine effective-
ness. Given the prevalence of exposure among controls,
the likelihood of none of the 11 children with conﬁrmed
inﬂuenza having been immunised with the pandemic
vaccine was 0.35. The OR of ILI associated with any
inﬂuenza vaccination was slightly lower than 1 (OR 0.9;
95% CI 0.1 to 5.5).
DISCUSSION
One of the main strengths of this study was the
promptness in adapting the protocol of an existing study
involving a network of hospitals to respond to the health
alert created by the pandemic emergency. Despite the
large Italian paediatric population enrolled, the results
concerning the safety and effectiveness of the pandemic
vaccine were partly inconclusive. Several reasons may
have contributed to this outcome. A-H1N1 vaccination
coverage in Italy during the 2009e2010 inﬂuenza season
was very low at around 4% of the population
13 and only
3.7% of the children included in the study. The inﬂu-
enza outbreak was almost over by the ﬁrst half of
December 2009, and both the incidence and severity of
the disease were lower than expected. As a consequence,
the Italian population did not adhere to the second part
of the immunisation campaign planned for January
2010. The epidemic curve during the 2009e2010 inﬂu-
enza season in Italy and the start of the vaccination
campaign are shown in ﬁgure 1. To further complicate
the picture, since A-H1N1 laboratory tests were
performed only during the epidemic phase, less than
10% of children hospitalised for ILI during the study
period were tested.
These difﬁculties were also observed in other Euro-
pean countries. A very low level of vaccination was found,
for instance, in the multinational European study
Inﬂuenza d Monitoring Vaccine Effectiveness
(I-MOVE),
14 which was a practitioner-based outpatient
surveillance study conducted in seven countries. Five of
the seven countries were unable to contribute more than
one vaccinated patient with conﬁrmed A-H1N1 inﬂu-
enza. Only the pooled analysis derived from the inter-
national collaboration was able to estimate vaccine
effectiveness.
Table 2 Children admitted with a diagnosis of AESI and
vaccinated with the pandemic vaccine
Diagnosis
Interval
(days)
Within the
risk period
Urticaria 20 No
Schoenlein-Henoch purpura 47 No
Urticaria 60 No
Vasculitis 128 No
Convulsions 149 No
Convulsions 188 No
AESI, adverse events of special interest.
Table 1 Distribution of children hospitalised for the study conditions
Conditions
Patients,
N (%)
Median
age (IQR)
Female,
N (%)
Exposed to
drug(s), N (%)
Exposed to
vaccine,* N (%)
Underlying
chronic
diseases, N (%)
Neurological disorders 241 (49) 4 (9) 112 (47) 166 (69) 53 (22) 35 (15)
Muco-cutaneous
diseases and vasculitis
144 (29) 5 (5) 53 (37) 110 (76) 18 (13) 14 (10)
Thrombocytopaenia 60 (12) 4 (7) 21 (35) 40 (67) 17 (28) 10 (17)
Gastroduodenal
lesions
47 (10) 5 (6) 20 (43) 33 (70) 8 (17) 6 (13)
Total 492 (100) 4 (7) 206 (42) 349 (71) 96 (20) 65 (13)
Inﬂuenza-like illness 244 3 (3) 108 (44) 170 (70) 77 (32) 58 (24)
*All vaccines administered to the study subjects, and not only those with inﬂuenza, are included; 25 children exposed to the pandemic vaccine
were distributed as follows: six cases (2.5%) were hospitalised for neurological disorders, 4 (2.8%) for muco-cutaneous diseases and vasculitis,
2 (4.3%) for gastroduodenal lesions and 13 (5.3%) for inﬂuenza-like illness. IQR, interquartile range.
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information on the beneﬁterisk proﬁle of the pandemic
vaccine. There were no reports of AESI associated with
vaccine use in children. These ﬁndings are consistent
with those reported by experimental and observational
studies, including analysis of spontaneous reporting
systems.
15e18 In conclusion, even with the limitation of
a low level of immunisation, no risk associated with the
A-H1N1 vaccine used in Italy was described. Among the
clinical diagnoses compatible with AESI, none was
reported in relation to vaccination in the predeﬁned risk
period.
Regarding effectiveness, as in other studies conducted
in adult populations, a strong confounding effect was
observed.
19 20 For instance, immunisation with the
seasonal vaccine was associated with a crude OR of >3.
Since the viruses included in the seasonal vaccine were
not circulating in the 2009e2010 season, this OR may
simply represent the effect of a greater prevalence of
inﬂuenza risk factors, mainly fragile patients, among
those immunised. Of note, when a protective effect was
expected, as for the pandemic vaccine, we observed
a wide difference between the crude and the adjusted
ORs (2.2 vs 1.3) associated with A-H1N1 vaccination. The
crude OR was adjusted by age and presence of chronic
diseases; the OR of A-H1N1 and the seasonal vaccine
were also adjusted for the other inﬂuenza vaccine. The
fact that even the adjusted OR remains above unity is
compatible with the presence of residual confounding
factors that we were unable to control for due to the
limited power of the study.
A required sample size of 194 children hospitalised for
ILI was estimated in the protocol. Despite the fact that
244 children with this diagnosis were enrolled, the power
proved inadequate given the low level of vaccination.
However, the sample size estimate, based on the
hypothesis that at least 50% of the paediatric population
had been vaccinated, was reliable at the time the
protocol was written.
As foreseen in the study protocol, a more valid esti-
mate of vaccine effectiveness was derived from the
comparison between test-positive and test-negative
ILIs.
16 Considering the reasonable hypothesis that
effectiveness is limited to the strains included in the
vaccine, cases of interest should concern hospitalisations
for ILI attributable to the inﬂuenza viruses against which
the vaccine was developed. Test-negative ILIs are there-
fore a valid control group (the source population of
cases). It would be impossible to differentiate between
cases and controls on the basis of the clinical symptoms
that prompted admission. Moreover, children hospital-
ised for an episode of ILI would more likely share similar
risk factors for inﬂuenza. Finally, since information on
vaccine status was collected in a similar way and in the
same setting for both cases and controls, recall bias can
be reasonably excluded.
In this study, we reported that given the low number of
children affected by ILI who underwent laboratory
testing, we could not estimate vaccine effectiveness (only
35 children were tested and no child who tested positive
for A-H1N1 had been vaccinated against the H1N1
virus). To support the assumption of a beneﬁcial effect
of pandemic vaccination, our ﬁndings need to be
corroborated by those of similar studies.
We consider it was worthwhile conducting the study
even though the ﬁndings might be considered only
exploratory. One of the main results of this process was
to test the usefulness of an integrated model for
conducting evaluations of the beneﬁterisk proﬁle of
vaccines in children.
Had the inﬂuenza pandemic been more severe and
prolonged, we would have been able to capture safety
signals as well as estimate vaccine effectiveness. However,
our ﬁndings may contribute to pooled estimates
together with those of similar investigations. Last but not
least, this study further supports the importance of active
hospital-based surveillance which can easily be adapted
Table 3 OR of inﬂuenza-like illness in association with immunisation status
Vaccines Cases (244) Controls (439) Crude OR (CI 95%) Adjusted* OR (CI 95%)
Any ﬂu vaccinesy 41 27 3.1 (1.8 to 5.3) 2.7 (1.6 to 4.7)
A-H1N1 vaccine 13 12 2.2 (0.9 to 5.3) 1.3 (0.6 to 3.1)
Seasonal vaccine 27 18 3.0 (1.6 to 5.9) 2.1 (1.1 to 4.1)
Not vaccinated 203 412 Reference e
Cases: all children hospitalised for ILI; controls: children hospitalised for thrombocytopaenia, gastroduodenal lesions, muco-cutaneous or
neurological conditions; only children above 6 months of age are included.
*Adjusted by age and chronic diseases; the ORs of A-H1N1 and seasonal vaccine were also adjusted for the other inﬂuenza vaccine.
yIn seven cases and two controls, the type of vaccine was not speciﬁed.
Table 4 OR of inﬂuenza-like illness in patients who tested
positive for A-H1N1 virus
Cases
(11)
Controls
(24)
Crude OR
(CI 95%)
Any ﬂu vaccines* 3 7 0.9 (0.1 to 5.5)
A-H1N1
vaccine
03e
Seasonal
vaccine
2 6 0.7 (0.1 to 5.3)
Not vaccinated 8 17 Reference
Cases: patients with inﬂuenza-like illness (ILI) who tested positive
for the A-H1N1 virus; controls: ILI patients who tested negative for
the A-H1N1 virus.
*In one case and one control, the type of vaccine was not speciﬁed.
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enza vaccines or new drugs.
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